A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score

Table 3 Outcomes of base-case analysis among alternative strategies

Start age	Strategies	Costs (CNY:million)	LYs (10,000 years)	QALYs (10,000 years)	ICER	ICUR
50	#0 Non-screening	1339.49	134.58	133.86
	#1 LDCT	1956.54	134.93	134.27	176,565.66	150,050.15
	#2 PRS&LDCT	1386.32	134.60	133.88	260,918.20	221,741.84
55	#0 Non-screening	1283.70	119.71	118.92
	#1 LDCT	1832.75	120.09	119.38	142,128.81	119,991.71
	#2 PRS&LDCT	1327.11	119.73	118.95	218,831.81	184,753.98
60	#0 Non-screening	1169.75	102.33	101.55
	#1 LDCT	1634.73	102.73	102.02	116,463.62	97,566.13
	#2 PRS&LDCT	1208.94	102.35	101.57	191,110.06	160,107.15
65	#0 Non-screening	950.81	82.70	82.03
	#1 LDCT	1309.47	83.04	82.45	104,998.56	85,332.16
	#2 PRS&LDCT	984.64	82.72	82.05	192,795.29	156,691.93
70	#0 Non-screening	631.94	60.26	59.83
	#1 LDCT	864.37	60.48	60.11	105,370.21	80,880.85
	#2 PRS&LDCT	659.40	60.27	59.84	242,247.42	185,958.48

Abbreviations: LDCT Low-dose computed tomography, PRS Polygenic risk score, CNY Chinese yuan, LYs Life years, QALYs Quality-adjusted life years, ICER Incremental cost-effectiveness ratio, ICUR incremental cost-utility ratio

ISSN: 1471-2407